It’s our pleasure to announce that Debiopharm is partnering with Frontiers Health for the second consecutive year!
Debiopharm, the Swiss biopharmaceutical company, develops, manufactures, and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and bacterial infections. Through their digital health investments, they provide funding and strategic guidance for companies with an ambition to improve the patient journey and re-imagine how clinical trials are conducted. Their portfolio company achievements include 10 FDA clearances, 13 CE marks, 2 IPOs, and 4 trade exits. Since 2008, they have invested over USD 120 million, typically leading the investment rounds of their 17 portfolio companies.
Debiopharm will curate a virtual breakout session ‘You’ve Got Your Series A Funding – Now What?’, addressing common issues that digital health startup founders face after getting the seed investment. The session panelists will share unique insights from their vast digital heath expertise.
Stay tuned to discover more!